Can Mesothelioma Be Cured By Pembrolizumab Now?

Pembrolizumab, an existing immunotherapy drug, is showing its magic in treating malignant pleural mesothelioma, according to the The Lancet Oncology.

Mesothelioma, is a rare and malignant cancer in your mesothelium, with which most patients will not survive for more than one year. It is a thin lining of tissue that covers the inside of the chest, the heart, the abdomen, and most internal organs.

Asbestos is the main risk factor  of  the mesothelioma whose fibers damage the mesothelial cells and cause scarring, mesothelioma, or both. You may see it commonly used in home and commercial construction.

Why the mesothelioma is so terrified?
Once diagnosed with mesothelioma, the patients are almost on its advanced stage. Its poor prognosis makes it horrible. Around 3000 new cases emerge every year in the united states, and there is no effective approved second-line treatments. The patients can only get the chemotherapy as their first-line therapy of the mesothelioma.

Cancer

Cancer

Mesothelioma is one of the malignant cancers.

Traditional treatment

Traditional treatment

The patients can only get the chemotherapy as their first-line therapy.

The lancet

The lancet

The Lancet takes the Pembrolizumab as a promising second-line treatment.

Pembrolizumab

Pembrolizumab

Here is the Pembrolizumab (Keytruda).

Doctor

Doctor

More tests remain to be done by researchers and doctors.

New pills

New pills

With the development of science and technology, more new treatments are coming soon!

However, recently, positive results have been shown in the Pembrolizumab (Keytruda). This is a drug that is helpful to your immune response against cancers, including non-small cell lung cancer, mesothelioma, and some other head and neck cancers.

Here is the detail about the pembrolizumab experiment:
Group: 25 patients with malignant pleural mesothelioma, all over 18.
Method: patients received a dose of pembrolizumab every 2 weeks for two years.
Result:  there are 14 patients experiencing the tumor shrinkage. The average overall survival of the mesothelioma was up to 18 months. In particular, there was a 6 months without progression. This is really exciting! Common side effects come in dry mouth, nausea, fatigue, and loss of appetite. According to experiment’s researchers, there were still 4 patients alive with mesothelioma receiving the treatments.


It’s clear that the a life expectancy of around 6 or 7 months can be expected with the Pembrolizumab against mesothelioma. Once more tests and experiments are conducted, we can get more data and evidence on mesothelioma treatment.  Besides, with the advance of science and technology, mesothelioma will definitely be shrunk and killed in future.

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.